Publication | Open Access

Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer

Erlotinib Versus ErlotinibMedicinePathologyImmune Checkpoint InhibitorBronchial NeoplasmCancer TreatmentIii TrialOncologyRadiation OncologyLung Cancer